How would you measure the success of Pear Therapeutics's reSET-O digital therapeutic for opioid use disorder?

Introduction

Measuring the success of Pear Therapeutics's reSET-O digital therapeutic for opioid use disorder requires a comprehensive approach that considers multiple stakeholders and metrics. To address this product success metrics challenge, I'll follow a structured framework covering core metrics, supporting indicators, and risk factors while considering all key stakeholders.

Step 1

Product Context

reSET-O is a prescription digital therapeutic (PDT) designed to treat opioid use disorder (OUD) in conjunction with buprenorphine and contingency management. It's a 12-week cognitive behavioral therapy (CBT) program delivered via a mobile application.

Key stakeholders include:

• Patients with OUD seeking treatment
• Healthcare providers prescribing and monitoring treatment
• Payers (insurance companies, government programs)
• Regulatory bodies (FDA, DEA)
• Pear Therapeutics (the company)

User flow:

1. Prescription: Healthcare provider prescribes reSET-O
2. Onboarding: Patient downloads app and enters prescription code
3. Engagement: Patient completes daily CBT modules and reports substance use
4. Monitoring: Provider reviews patient progress through clinician dashboard
5. Completion: Patient finishes 12-week program

reSET-O fits into Pear Therapeutics' strategy of developing PDTs for various mental health and substance use disorders. It's part of a growing trend of digital health solutions aimed at improving access to and effectiveness of behavioral health treatments.

Competitors include other digital health platforms for addiction treatment (e.g., DynamiCare Health, Quit Genius) and traditional in-person therapy programs. reSET-O differentiates itself through its FDA approval and integration with medication-assisted treatment.

Product Lifecycle Stage: Growth phase. reSET-O received FDA clearance in 2018 and is still expanding its user base and market presence.